Alexandre Bolze, Ph.D.

Associate Professor

Schools: Medical School
Departments: Eugene McDermott Center for Human Growth and Development | Internal Medicine

Biography

Dr. Alexandre Bolze is an Associate Professor in the McDermott Center for Human Growth and Development at UT Southwestern Medical Center and the Principal Investigator of SPARC (Sequencing Populations to Accelerate Research and Care), a major institutional initiative to build a biobank integrating genomic and clinical data from more than 150,000 participants.

Dr. Bolze is a human geneticist whose research uses large-scale biobanks to study disease-risk, resilience and prevention. His work includes evaluating the clinical impact of pathogenic variants in CDC Tier 1 genes, developing population screening approaches that combine rare variants and polygenic risk scores, and investigating the genetics of disease resistance. He also studies the genetics of immune responses to various triggers including vaccination.

Before joining UT Southwestern in 2025, Dr. Bolze was a Principal Scientist at Helix, where he helped develop population genomic programs with health systems across the United States. His earlier work helped identify genetic causes of severe pediatric infectious diseases through the use of whole-exome sequencing, including isolated congenital asplenia.

Publications

Featured Publications

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection.: Marchal A, Cirulli ET, Neveux I, Bellos E, Thwaites RS, Schiabor Barrett KM, Zhang Y, Nemes-Bokun I, Kalinova M, Catchpole A, Tangye SG, Spaan AN, Lack JB, Ghosn J, Burdet C, Gorochov G, Tubach F, Hausfater P, Dalgard CL, Zhang SY, Zhang Q, Chiu C, Fellay J, Grzymski JJ, Sancho-Shimizu V, Abel L, Casanova JL, Cobat A, Bolze A, HGG Adv 2024 Jul 5 3 100300
The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer.: Bolze A, Cirulli ET, Hajek C, Schnell Blitstein JM, Grzymski JJ, JAMA Oncol 2024 Feb 10 2 236-239
HLA-A∗03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination.: Bolze A, Neveux I, Schiabor Barrett KM, White S, Isaksson M, Dabe S, Lee W, Grzymski JJ, Washington NL, Cirulli ET, HGG Adv 2022 Apr 3 2 100084
Ribosomal protein SA haploinsufficiency in humans with isolated congenital asplenia.: Bolze A, Mahlaoui N, Byun M, Turner B, Trede N, Ellis SR, Abhyankar A, Itan Y, Patin E, Brebner S, Sackstein P, Puel A, Picard C, Abel L, Quintana-Murci L, Faust SN, Williams AP, Baretto R, Duddridge M, Kini U, Pollard AJ, Gaud C, Frange P, Orbach D, Emile JF, Stephan JL, Sorensen R, Plebani A, Hammarstrom L, Conley ME, Selleri L, Casanova JL, Science 2013 May 340 6135 976-8
Whole-exome-sequencing-based discovery of human FADD deficiency.: Bolze A, Byun M, McDonald D, Morgan NV, Abhyankar A, Premkumar L, Puel A, Bacon CM, Rieux-Laucat F, Pang K, Britland A, Abel L, Cant A, Maher ER, Riedl SJ, Hambleton S, Casanova JL, Am J Hum Genet 2010 Dec 87 6 873-81
Dominant negative ADA2 mutations cause ADA2 deficiency in heterozygous carriers.: Wouters M, Ehlers L, Van Eynde W, Kars ME, Delafontaine S, Kienapfel V, Dzhus M, Schrijvers R, De Haes P, Struyf S, Bucciol G, Itan Y, Bolze A, Voet A, Hombrouck A, Moens L, Ogunjimi B, Meyts I, J Exp Med 2025 Nov 222 11
Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia.: Levy ME, Schiabor Barrett KM, Betts MN, Kann D, Bolze A, Khuder B, Telis N, McEwen LM, Sturm AC, Haldeman-Englert C, Cauwels J, Stoller D, Chahal CAA, Chapman CN, Waring AA, Olson DA, Grzymski JJ, Washington NL, Lee W, Cirulli ET, Hajek C, Circ Genom Precis Med 2025 Nov e005206
The seven enigmas of SARS-CoV-2: from the past to the future.: Andreakos E, Arkin L, Bastard P, Bolze A, Borghesi A, Brodin P, Casanova JL, Casari G, Cobat A, Drolet B, Fellay J, Hsieh E, Meyts I, Mogensen TH, Sancho-Shimizu V, Spaan AN, Su HC, Vinh DC, Yatim A, Zhang Q, Zhang SY, J Hum Immun 2025 Nov 1 4
Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort.: Telis N, Dai H, Waring A, Kann D, Wyman D, White S, Khuder B, Tanudjaja F, Bolze A, Levy ME, Hajek C, McEwen LM, Stoller D, Chapman CN, Chahal CAA, Judge DP, Olson DA, Grzymski JJ, Washington NL, Lee W, Cirulli ET, Luo S, Schiabor Barrett K, JACC Basic Transl Sci 2025 Oct 10 10 101298
Hypertension increases PPV for polycystic kidney disease in PKD1 and PKD2 variant carriers.: Telis N, McEwen L, Bolze A, Lipschutz JH, Sweer LW, Judge DP, Pawloski PA, Grzymski JJ, Hajek C, Schiabor Barrett KM, Washington NL, Cirulli ET, HGG Adv 2025 Jul 6 3 100444